Tender 2008 - letter to pharmaceutical suppliers and interested parties - ACPs close 15 October, other responses close 5 November 2008 (text extract)

This is the text extract for Tender 2008 - letter to pharmaceutical suppliers and interested parties - ACPs close 15 October, other responses close 5 November 2008, browse documents here.

24 September 2008 To: Pharmaceutical Suppliers and Interested Parties Consultation on: · Tender of certain pharmaceuticals; · Draft Invitation to Tender; and · Requests for Alternative Commercial Proposals.

ALTERNATIVE COMMERICAL PROPOSAL RESPONSES DUE BY

5 PM, WEDNESDAY 15 OCTOBER 2008

AND ALL OTHER CONSULTATION RESPONSES BY

5 PM, WEDNESDAY 5 NOVEMBER 2008

Comments Sought In general, the proposed Tender process would be similar to the 2007/08 Tender. In addition to Alternative Commercial Proposals that are discussed later, we seek comments on the approach outlined in the following pages, in particular the following: · · · The proposed process and timetable. An indication of any pharmaceuticals, whether or not included in Schedule Two, that you think would be inappropriate to tender, and the reasons for that. An indication of any pharmaceuticals, whether or not they are included in Schedule Two, that you would particularly like to have tendered. If you wish, you may provide a non-binding confidential indication of the price or price range that you might be able to offer for a line item or group of line items you wish to have tendered. Any contractual constraints or patent protection that could restrict PHARMAC from implementing a Tender. For Hospital pharmaceuticals what the appropriate Discretionary Variance Limit for each pharmaceutical would be, where a 1% Discretionary Variance Limit is considered clinically unacceptable.

· ·

We seek comments on all sections of the draft Invitation. The draft Invitation is based on the format of the Invitation to Tender dated 21 December 2007 for community supply and/or hospital supply. All feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and would be considered by the PHARMAC Board. Alternative Commercial Proposals PHARMAC seeks any Alternative Commercial Proposals (ACPs) to tendering that you may wish to submit by Wednesday 15 October 2008. A proposal could, for example,involve price reductions on one set of pharmaceuticals in return for PHARMAC agreeing to defer tendering on another group of pharmaceuticals for a period. Proposals may include pharmaceuticals not listed in Schedule Two.

A228456 - qA12214

Please note the following points with regard to ACPs for both the community and DHB Hospital markets: · · Proposals may include more than one line item and may include pharmaceuticals not listed in Schedule Two. Proposals may involve PHARMAC agreeing to defer tendering or application of reference pricing as a result of the Tender for a period of no longer than three years for any pharmaceutical, whether or not it is listed in Schedule Two (the draft product list). Proposals must not involve PHARMAC agreeing to award Sole Subsidised Supply in the community but may include the awarding of Hospital Supply Status for DHB Hospital pharmaceuticals. PHARMAC reserves the right: o not to accept any proposal; and/or o not to provide reasons for the acceptance or non-acceptance of any proposal; and/or o to enter into an agreement or arrangement that differs in a material respect from that envisaged in this letter. PHARMAC may decide not to consider any proposal that is submitted after Wednesday 5pm, 15 October 2008.

Draft Invitation to Tender PHARMAC is consulting on the terms and conditions of the proposed Invitation to be considered by the PHARMAC Board at its December 2008 meeting. Please find the draft list of products to be tender enclosed. A complete copy of the draft Invitation to Tender is available on our website (www.pharmac.govt.nz), which PHARMAC proposes all Tender Bids would be subject to, including the terms of supply, if a Tender Bid was accepted by the PHARMAC Board (or the Chief Executive under delegated authority). The draft Invitation is under development and may change before it is taken to the December Board and the final Invitation subsequently issued. PHARMAC is asking for comments on the composition of the draft Invitation. At this stage, but depending on the extent of any further changes, PHARMAC does not intend to send out any further drafts for consultation. Any feedback regarding the draft Invitation should be received by PHARMAC no later than 5pm, 5 November 2008. Late feedback may not be considered. Consultation feedback received by the due date will be presented to the PHARMAC Board for consideration before it makes its decision. The draft Invitation is set out as follows: Schedule 1: Schedule 2: Definitions and interpretation; Draft list of pharmaceuticals to be tendered. The final pharmaceutical list would be released with the Invitation to Tender following Board approval (please note that the list may change following consultation, and that you may provide feedback on the inclusion of pharmaceuticals once the tender has been issued, and that feedback will be considered by the Board (or Chief Executive) before making a final decision on any tender provided that the feedback is given before the tender close date in early 2009);

A228456 - qA12214

Schedule 3: Schedule 4: Schedule 5: Schedule 6:

Tender process (for both hospital and community Tenders); Contract terms for Sole Subsidised Supply and/or Hospital Supply Status; Additional contract terms for Sole Subsidised Supply; Additional contract terms for Hospital Supply Status.

The main change is described below: Pharmaceutical Cancer Treatments (PCTs) PHARMAC proposes to amend the provisions for the transitional PCT budget in Clause 11 of Schedule 6 of the Invitation to Tender by removing Clause 11.2 (a)(i) and Clause 11.2 (a)(ii). We consider that this clause is no longer required given the changes that have occurred to the management of PCTs. Access to Alternative Brands PHARMAC is continuing work to identify mechanisms that can reduce the impact on patients of brand changes. We will keep you informed as this work continues to progress. In the meantime, PHARMAC has undertaken a preliminary assessment to determine which products are appropriate for inclusion in this years’ tender. We welcome specific comments in relation to the implications of tendering items included in Schedule Two. Electronic Tender (eTender) system Following the successful implementation of the eTender system as part of the 2007/08 Tender, PHARMAC will continue to use the eTender system for the 2008/09 Tender. The final 2008/09 Invitation to Tender will distributed via the eTender system and a test of email addresses will occur in December 2008. We have received valuable feedback from suppliers, which has helped us to highlight areas where improvements can be made. We will be working closely with our service provider to improve the system. Unresolved Tender Bids PHARMAC would review any unresolved Tender Bids from the Invitation to Tender dated 15 December 2006 (2006/07 Tender) and the Invitation to Tender dated 21 December 2007 (2007/08 Tender) prior to issuing the 2008/09 Tender. Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the Invitation to Tender is issued in December 2008. Any unresolved Tender Bids have not been included in the draft pharmaceutical list. PHARMAC seeks comments from suppliers that consider that any unresolved Tender Bid(s) should remain open for acceptance. Reference Pricing Reference pricing is based on the classification of pharmaceuticals into Therapeutic Subgroups. A Therapeutic Subgroup is defined as a set of pharmaceuticals that produce the same or similar therapeutic effect in treating the same or similar condition(s). The draft list contains pharmaceuticals that belong in an existing Therapeutic Subgroup. In some cases, PHARMAC may be considering tendering more than one pharmaceutical in a

A228456 - qA12214

Therapeutic Subgroup. including:

Where this is the case it gives rise to a number of scenarios

1) It is possible that awarding Sole Subsidised Supply to one pharmaceutical could result in changes to the subsidies for other pharmaceuticals in the same Therapeutic Subgroup. 2) Where more than one pharmaceutical in a Therapeutic Subgroup is included on the list, PHARMAC may award Sole Subsidised Supply to each pharmaceutical (and therefore not apply reference pricing in the usual way) or may only award Sole Subsidised Supply to one pharmaceutical and apply reference pricing to the others. Such scenarios could give rise to new or increased manufacturer surcharges. We ask that you consider any clinical considerations associated with such scenarios.

Key Dates and Timeframes for the 2008/09 Tender: Date

September/October 2008 15 October 2008 (5pm) 5 November 2008 (5pm) November 2008 November 2008 November/December 2008 Late December 2008 Late February 2009 From March 2009 30 June 2012

Event

Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender. Final date for receipt of Alternative Commercial Proposals to tendering by PHARMAC. Final date for all consultation to be received. PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC’s Decision Criteria and enters into provisional contracts with suppliers where appropriate. Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list. Consultation and Board decisions on Alternative Commercial Proposals. Issuing of the 2008/09 Invitation to Tender. Invitation to Tender closes. Board decisions on the first Tender winners announced. End of the sole supply period for all pharmaceuticals where a Tender is awarded from the 2008/09 Tender. Terms after the End Date may apply.

Please direct any queries you may have to Yvonne Chen [DDI: (04) 916 7556] at PHARMAC for questions in relation to community supply, and Andrew Davies [DDI: (04) 916 7531] for questions in relation to hospital supply. Yours sincerely

Steffan Crausaz Manager, Funding and Procurement

A228456 - qA12214

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Abacavir Sulphate Oral liq 20 mg per ml Tab 300 mg Abacavir sulphate with lamivudine Tab 600 mg with lamivudine 300 mg Acarbose Tab 50 mg Tab 100 mg Acetylcholine Inj 10 mg per ml, 2 ml Aciclovir Inj 250 mg Inj 500 mg Inj 1,000 mg Tab 200 mg H H H C H 1% 1% 1% 1%

Dispersible tablets need to remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly. Not currently listed on the Pharmaceutical Schedule. Dispersible tablets need to remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly. Not currently listed on the Pharmaceutical Schedule. Dispersible tablets need to remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly. Not currently listed on the Pharmaceutical Schedule.

Units

Cost

Unit Subsidy

DV Limit

Comments

26,298 72,537

$10,958 $553,699

$0.4167 $7.6333

C H C H

1% 1%

36,458

$765,618

$21.0000

+ C H

501,151 178,370

$122,504 $61,439

$0.2444 $0.3444

C H C H

1% 1%

Tab 400 mg

C H

Tab 800 mg

C H

Tab dispersible 200 mg Tab dispersible 400 mg Tab dispersible 800 mg Acitretin Cap 10 mg Cap 25 mg Alprostadil Inj 0.5 mg per ml, 1 ml Amikacin Inj 5 mg per ml, 5 ml Inj 250 mg per ml, 2 ml

815,115 3,046,791 497,147

$64,557 $361,349 $104,848

$0.0792 $0.1186 $0.2109

C H C H C H

1% 1% 1%

286,675 87,123

$271,625 $177,470

$0.9475 $2.0370

C C

H H

1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Amoxycillin Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Sachets 3 g 29,891,936 22,765,928 $298,919 $289,127 $0.0100 $0.0127 C H C H C H 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

Amoxycillin Clavulanate Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Amphotericin B Emulsion for infusion 5 mg per ml Liposomal Inj 50 mg C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed in the Pharmaceutical Schedule

12,012,266

$330,337

$0.0275

C H

15,612,478

$741,593

$0.0475

C H

Amsacrine Inj 50 mg per 1 ml Apomorphine Hydrochloride Inj 10 mg per ml, 1 ml Aprotinin Inj 10,000,000 iu per ml, 50 ml Inj 10,000 mcg per ml, 100 ml Inj 10,000 mcg per ml, 200 ml * C H C H C H 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

8,036

$81,051

$10.0860

C H

Arginine Inj 5%, 500 ml Ascorbic Acid Inj 500 mg per 5 ml Tab 50 mg Tab 100 mg Tab 250 mg 1,163,211 $40,131 $0.0345 H C H C H C H 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Atenolol Tab 50 mg Tab 100 mg Atorvastatin Tab 10 mg Tab 20 mg Tab 40 mg 4,043,571 5,720,682 7,361,373 $543,052 $1,119,537 $1,997,140 $0.1343 $0.1957 $0.2713 * * *

+ C + C + C

9,451,084 3,407,916

$122,864 $77,019

$0.0130 $0.0226

C H C H

1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Atorvastatin Tab 80 mg

+ C Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

Atracurium Besylate Inj 10 mg per ml, 2.5 ml Inj 10 mg per ml, 5 ml Atropine Sulphate Inj 400 mcg, 1 ml Inj 600 mcg, 1 ml Inj 1200 mcg, 1 ml Azithromycin Tab 500 mg Baclofen Inj 10 mg Oral liq 5 mg per 5 ml Tab 10 mg Tab 20 mg C H C H C H C H 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceuticcal Schedule Not currently listed on the Pharmaceutical Schedule

H H

1% 1%

C H 74,203 8,555 $38,586 $5,475 $0.5200 $0.6400 C H C H

1% 1% 1%

Not currently listed in the Pharmaceutical Schedule

93,956

$465,082

$4.9500

C H

Beclomethasone Dipropionate Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Beractant Inj 25 mg per ml, 8 ml Betamethasone Valerate Scalp app 0.1% Betaxolol Hydrochloride Eye drops 0.25% Eye drops 0.5% Bimatoprost Eye Drops 0.03% Bleomycin sulphate Inj 15,000 iu Budesonide Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Nebuliser soln, 500 mcg per ml, 2 ml 5,253,314 29,732,447 $61,726 $388,008 $0.0118 $0.0131 * * C H C H H 1% 1% 1% H PCT 1% 115,766 $752,479 $6.5000 C 65,418 9,179 $154,386 $13,769 $2.3600 $1.5000 C C 3,105,621 $163,045 $0.0525 C H 1% H 1% 11,712,396 44,054,856 $137,621 $541,875 $0.0118 $0.0123 C H C H 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Budesonide Nebuliser soln, 1 mg per ml, 2 ml Bupivacaine hydrochloride Inf 0.125%, 100 ml Inf 0.125%, 200 ml Inf 0.25%, 100 ml Inj 0.25%, 20 ml Inj 0.375%, 20 ml Inj 0.5%, 4 ml theatre pack Inj 0.5%, 10 ml Inj 0.5%, 10 ml Theatre pack Inj 0.5%, 20 ml Inj 0.5%, 20 ml Theatre pack Bupivacaine Hydrochloride with Adrenaline Inj 0.25% with 1:400,000 of adrenaline, 10 ml Inj 0.25% with 1:400,000 of adrenaline, 10 ml theatre pack Inj 0.25% with 1:400,000 of adrenaline, 20 ml Inj 0.25% with 1:400,000 of adrenaline, 20 ml theatre pack Inj 0.5% with 1:200,000 of adrenaline, 10 ml Inj 0.5% with 1:200,000 of adrenaline, 10 ml theatre pack Inj 0.5% with 1:200,000 of adrenaline, 20 ml Inj 0.5% with 1:200,000 of adrenaline, 20 ml theatre pack Calamine Crm, aqueous, BP Lotn, BP Calcitriol Cap 0.25 mcg Cap 0.5 mcg Calcium Carbonate with Aminoacetic Acid Tab 400-420 mg with aminoacetic acid 180 mg 1,309,386 $39,282 $0.0300 C H 1%

Dose range of 400-420 mg elemental calcium per tablet required

Units

Cost

Unit Subsidy

DV Limit

Comments

H H H H H H H H H H

1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

H H

1% 1%

H H

1% 1%

H H

1% 1%

H H

1% 1%

176,113 4,284,946

$5,319 $41,650

$0.0302 $0.0097

C C

2,655,022 374,927

$357,100 $93,544

$0.1345 $0.2495

C H C H

1% 1%

Calcium Gluconate Inj 10%, 10 ml 1,666 $3,565 $2.1400 C H 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Capecitabine Tab 150 mg Tab 500 mg Carboplatin Inj 10 mg per ml, 5 ml Inj 10 mg per ml, 10 ml Inj 10 mg per ml, 15 ml Inj 10 mg per ml, 45 ml Inj 10 mg per ml, 100 ml Carmustine Inj 100 mg, 3 ml Caspofungin Inj 50 mg Inj 70 mg Cefazolin Sodium Liq C H 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

613,071 117,595

$3,601,792 $225,394

$5.8750 $1.9167

C H C H

1% 1%

H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1%

H PCT 1%

H H

1% 1%

Celiprolol Tab 200 mg Cephradine Liq C H 1%

Not currently listed on the Pharmaceutical Schedule

6,179,652

$652,571

$0.1056

C H

Chloramphenicol Eye drops 0.5% Eye oint 1% Chlorhexidine Crm 1% obstetric Chlorhexidine Gluconate Handrub 0.5% - 1% with ethanol 70% 2,168,302 $23,418 $0.0108 C

Chlorhexidine strengths from 0.5% to 1% would be considered

1,671,053 451,236

$233,947 $279,766

$0.1400 $0.6200

C H C H

1% 1%

Single dose presentation would not be a DV Pharmaceutical

Chloroquine Oral liq Tab 200 mg - 250 mg C C

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Chlorpheniramine Maleate Cap long-acting 12 mg C H 1%

Not currently subsidised on the Pharmaceutical Schedule

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Ciclopiroxolamine Crm 1% Nail soln 8% Soln 1% Clobetasol Propionate Crm 0.05% Oint 0.05% Scalp app 0.05% Clomiphene Citrate Tab 50 mg Clonidine Inj 150 mcg per ml, 1 ml Tab 25 mcg Tab 150 mcg TDDS 2.5 mg, 100 mcg per day TDDS 5 mg, 200 mcg per day TDDS 7.5 mg, 300 mcg per day Cocaine Soln 4%, 2 ml BP Cyclizine Hydrochloride Tab 50 mg Cyclizine Lactate Inj 50 mg per ml, 1 ml Cyclosporin Inf 50 mg per ml, 5 ml Cyproterone Acetate Tab 50 mg Tab 100 mg 996,277 $468,250 $0.4700 C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

36,090 58,828 35,599

$1,805 $635,510 $7,761

$0.0500 $10.8029 $0.2180

* * *

C C C

2,450,584 2,357,714 595,476

$191,962 $125,745 $63,517

$0.0783 $0.0533 $0.1067

C H C H C H

1% 1% 1%

44,271

$22,136

$0.5000

8,495 2,622,929 507,228 36,752 12,937 9,885

$23,786 $459,799 $153,842 $195,613 $99,583 $96,626

$2.8000 $0.1753 $0.3033 $5.3225 $7.6975 $9.7750

C H C H C H C H C H C H

1% 1% 1% 1% 1% 1%

677,078

$134,739

$0.1990

C H

56,899

$170,128

$2.9900

C H

Dacarbazine Inj 200 mg Daclizumab Inj 25 mg per 5 ml Danazol Cap 100 mg Cap 200 mg 12,211 30,018 $10,175 $17,011 $0.8333 $0.5667 C H C H 1% 1% H 1% H PCT 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Dantrolene Sodium Cap 25 mg Cap 50 mg Inj 1 mg per ml, 20 ml Dexamethasone Sodium Phosphate Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Diazepam Rectal tubes 5 mg Rectal tubes 10 mg Diclofenac Sodium Cap long-acting 100 mg Tab 50 mg dispersible Tab EC 25 mg Tab EC 50 mg Tab long-acting 75 mg Tab long-acting 100 mg Dicloxacillin Inj 500 mg C H 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

130,888 53,732

$43,141 $27,779

$0.3296 $0.5170

C H C H H

1% 1% 1%

19,530 72,426

$83,979 $449,041

$4.3000 $6.2000

C H C H

1% 1%

11,015 15,928

$61,309 $246,151

$5.5660 $15.4540

C H C H

1% 1%

C H 813,172 498,946 3,827,691 21,240,802 4,444,439 $60,988 $17,513 $198,121 $967,731 $305,066 $0.0750 $0.0351 $0.0518 $0.0456 $0.0686 C H C H C H C H C H

1% 1% 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

Dobutamine Inj 12.5 mg per ml, 20 ml Dopamine Inj 40 mg per ml, 5 ml Dorzolamide Hydrochloride Eye drops 2% Dorzolamide hydrochloride with timolol maleate Eye drops 2% with timolol maleate 0.5% Doxorubicin Inj 10 mg Inj 20 mg Inj 50 mg Inj 100 mg Inj 200 mg Enalapril Tab 2.5 mg C H 1%

Not currently listed on the Pharmaceutical Schedule

27,856

$54,431

$1.9540

323,288

$1,196,166

$3.7000

+ C H

H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Enalapril Tab 5 mg Tab 10 mg Tab 20 mg Enalapril With Hydrochlorothiazide Tab 20 mg with hydrochlorothiazide 12.5 mg Entacapone Tab 200 mg Ephedrine Sulphate Inj 30 mg per ml, 1 ml Epirubicin Inj 1 mg per ml, 5 ml Inj 2 mg per ml, 2 ml Inj 2 mg per ml, 5 ml Inj 2 mg per ml, 10 ml Inj 2 mg per ml, 25 ml Inj 2 mg per ml, 50 ml Inj 2 mg per ml, 100 ml Ergometrine Maleate Inj 500 mcg per ml, 1 ml Ergotamine Tartrate with Caffeine Tab 1 mg with caffeine 100 mg Erythromycin Ethyl Succinate Tab 400 mg Ethinyloestradiol Tab 10 mcg Etidronate Disodium Tab 200 mg Etoposide Cap 50 mg Cap 100 mg Inj 20 mg per ml, 20 ml Inj 20 mg per ml, 50 ml Famotidine Tab 20 mg Tab 40 mg 794,073 663,356 $25,728 $30,116 $0.0324 $0.0454 C C 6,196 1,059 $105,558 $36,083 $17.0365 $34.0730 C H PCT 1% C H PCT 1% H PCT 1% H PCT 1% 1,719,628 $653,459 $0.3800 C H 1% 305,869 $53,833 $0.1760 C 4,664,291 $883,883 $0.1895 C H 1% 462,764 $143,457 $0.3100 C H 1% 2,106 $4,886 $2.3200 C H 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% 391,751 $505,359 $1.2900 C H 1% 426,921 $47,246 $0.1107 * C H 1% 4,518,231 3,869,420 3,152,044 $109,944 $118,662 $128,884 $0.0243 $0.0307 $0.0409 C H C H C H 1% 1% 1% Units Cost Unit Subsidy DV Limit Comments

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Felodipine Tab long-acting 2.5 mg Tab long-acting 5 mg Tab long-acting 10 mg Fentanyl Inj 50 mcg per ml, 2 ml Inj 50 mcg per ml, 5 ml Inj 50 mcg per ml, 10 ml Inj 50 mcg per ml, 20 ml C H C H C H C H 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

8,177,612 14,589,483 10,114,257

$2,829,454 $2,674,739 $2,697,135

$0.3460 $0.1833 $0.2667

C H C H C H

1% 1% 1%

Filgrastim Inj 0.3 mg per ml, 1 ml Flecainide Acetate Cap long-acting 100 mg Cap long-acting 200 mg Inj 10 mg per ml, 15 ml Tab 50 mg Tab 100 mg Flucloxacillin Sodium Cap 250 mg Cap 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Fluconazole Inj 2 mg per ml, 50 ml Fluorometholone Eye drops 0.1% Folic Acid Tab 0.8 mg Tab 5 mg Frusemide Tab 40 mg Tab 500 mg 36,001,746 220,562 $414,020 $26,467 $0.0115 $0.1200 C H C H 1% 1% 2,762,493 5,910,478 $45,581 $77,900 $0.0165 $0.0132 C C 64,020 $55,057 $0.8600 C H 1% H 1% 1,289,694 7,610,215 4,295,279 5,616,300 $95,437 $881,263 $88,053 $152,763 $0.0740 $0.1158 $0.0205 $0.0272 C H C H C H C H 1% 1% 1% 1% 648,558 522,648 18 249,598 239,890 $925,687 $1,317,596 $176 $178,138 $302,381 $1.4273 $2.5210 $9.8040 $0.7137 $1.2605 C H C H C H C H C H 1% 1% 1% 1% 1% H 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Gabapentin Cap 100 mg 895,270 $118,713 $0.1326 C H 5%

Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two.

Units

Cost

Unit Subsidy

DV Limit

Comments

Cap 300 mg

6,568,959

$2,613,789

$0.3979

C H

Cap 400 mg

814,273

$431,646

$0.5301

C H

Tab 600 mg

43,134

$34,417

$0.7979

C H

Gemfibrozil Cap 300 mg

Not currently listed on the Pharmaceutical Schedule

Gentamicin Sulphate Inj 40 mg per ml, 2 ml Glyceryl Trinitrate Inj 1 mg per ml, 5 ml Inj 1 mg per ml, 50 ml Inj 5 mg per ml, 1 ml Inj 5 mg per ml, 10 ml Glycopyrronium Inj 0.2 mg per ml, 1 ml Hydralazine Inj 20 mg per ml, 1 ml Hydrochlorothiazide Tab 12.5 mg Tab 25 mg C C

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

6,288

$2,867

$0.4560

C H

H H H H

1% 1% 1% 1%

463

$2,398

$5.1800

C H

Hydrocortisone Crm 1% (pack size 15 g or less) 17,399,193 $424,540 $0.0244 C H 1%

Volume is aggregated for all pack sizes of hydrocortisone cream Volume is aggregated for all pack sizes of hydrocortisone cream

Crm 1% (pack size greater than 15 g and 100 g or less) Tab 5 mg

17,399,193

$424,540

$0.0244

C H

2,440,393

$194,011

$0.0795

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Hydrocortisone Tab 20 mg Hydrocortisone Acetate Rectal foam 10 %, CFC-free Hydrocortisone with Miconazole Crm 1% with miconazole nitrate 2% Hydroxocobalamin Inj 1 mg per ml, 1 ml 229,445 $704,396 $3.0700 C H 1%

Currently two different subsidies, unit subsidy reflects the lower of the two

Units

Cost

Unit Subsidy

DV Limit

Comments

141,826

$28,294

$0.1995

C H

246,692

$246,692

$1.0000

C H

3,308,557

$485,365

$0.1467

Idarubicin hydrochloride Cap 5 mg Cap 10 mg Inj 5 mg Inj 10 mg Imipramine Hydrochloride Tab 10 mg Tab 25 mg Iodine Soln aqueous BP C

Not currently listed on the Pharmaceutical Schedule. A Special Authority or endorsement (for use during pregnancy and breast-feeding only) may be applied. Not currently listed on the Pharmaceutical Schedule. A Special Authority or endorsement (for use during pregnancy and breast-feeding only) may be applied. A combination product would be considered; however it must contain 150 mcg -200 mcg of iodine.

H PCT 1% H PCT 1% H PCT 1% H PCT 1%

480,347 1,637,443

$84,541 $179,464

$0.1760 $0.1096

C H C H

1% 1%

Tab 150-200 mcg

Irinotecan Inj 20 mg per ml, 2 ml Inj 20 mg per ml, 5 ml Isotretinoin Cap 10 mg 1,079,577 $388,648 $0.3600 C H 1%

Information on appropriate use should be available on a website Information on appropriate use should be available on a website. Information on appropriate use should be available on a website. Not currently listed on the Pharmaceutical Schedule.

H PCT 1% H PCT 1%

Cap 20 mg

1,942,915

$922,885

$0.4750

C H

Cap 40 mg

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Ketamine Inj 100 mg per ml, 2 ml Lamivudine Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 100 mg Tab 150 mg Lansoprazole Cap 15 mg Cap 30 mg Leflunomide Tab 10 mg Tab 20 mg Tab 100 mg Letrozole Tab 2.5 mg Levodopa with Benserazide Cap 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Tab dispersible 50 mg with benserazide 12.5 mg Lignocaine Gel 2% Lisinopril Tab 2.5 mg Tab 5 mg Tab 10 mg Tab 20 mg Lisinopril with Hydrochlorothiazide Tab 20 mg with hydrochlorothiazane 12.5 mg C H 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

240 83,825 299,522 80,464

$90 $34,930 $1,529,689 $411,976

$0.3750 $0.4167 $5.1071 $5.1200

C C C C

134,230 1,155,646

$20,618 $354,536

$0.1536 $0.3068

C H C H

1% 1%

163,670 388,518 25

$432,471 $1,406,435 $454

$2.6423 $3.6200 $18.1467

C H C H C H

1% 1% 1%

403,568

$1,970,219

$4.8820

C H

1,017,949 1,218,285 654,911 153,844 580,338

$81,436 $152,286 $111,335 $38,461 $58,034

$0.0800 $0.1250 $0.1700 $0.2500 $0.1000

C H C H C H C H C H

1% 1% 1% 1% 1%

C H 606,533 575,487 717,210 $56,205 $60,618 $93,476 $0.0927 $0.1053 $0.1303 C H C H C H

1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

Lorazepam Tab 1 mg Tab 2.5 mg 4,401,220 256,674 $110,559 $10,575 $0.0251 $0.0412 C H C H 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Losartan Tab 12.5 mg Tab 25 mg Tab 50 mg Tab 100 mg Tab 50 mg with hydrochlorothiazide 12.5 mg Tab 100 mg with hydrochlorothiazide 25 mg 1,423,394 105 2,186,442 165,131 569,215 $825,569 $76 $1,683,560 $194,855 $569,215 $0.5800 $0.7254 $0.7700 $1.1800 $1.0000 C H C H C H C H C H C H 1% 1% 1% 1% 1% 1%

Not currently listed in the Pharmaceutical Schedule This was recently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

Magnesium Sulphate Inj 49.3%, 5 ml Maprotiline Hydrochloride Tab 25 mg Tab 75 mg Mesalazine Enema 1 g per 100 ml Metaraminol Tartrate Inj 10 mg per ml, 1 ml Metformin Hydrochloride Tab 500 mg Tab 850 mg Methadone Hydrochloride Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Methotrexate Tab 2.5 mg Tab 10 mg Methylphenidate Hydrochloride Tab immediate-release 5 mg Tab immediate-release 20 mg Tab immediate-release 10 mg Tab sustained-release 20 mg 102,380 34,071 2,350,074 2,445,000 $10,924 $8,916 $336,061 $892,425 $0.1067 $0.2617 $0.1430 $0.3650 C H C H C H C H 1% 1% 1% 1%

Excludes long-acting or extended-release products

92,569 16,952

$23,198 $11,871

$0.2506 $0.7003

C H C H

1% 1%

44,152

$295,818

$6.7000

C H

65,764,349 14,906,417

$1,282,405 $477,005

$0.0195 $0.0320

C H C H

1% 1%

2,398,374 20,903,093 2,995,585

$78,547 $681,441 $142,290

$0.0328 $0.0326 $0.0475

C H C H C H

1% 1% 1%

1,816,012 254,883

$351,096 $208,647

$0.1933 $0.8186

C H PCT 1% C H PCT 1%

Methylprednisolone Inj 500 mg Inj 1 g 308 290 $5,067 $12,345 $16.4500 $42.5700 C H C H 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Methylprednisolone Tab 4 mg Tab 100 mg Methylprednisolone Sodium Succinate Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Metoclopramide Hydrochloride with Paracetamol Tab 5 mg with paracetamol 500 mg Miconazole Oral gel 20 mg per g Midazolam Inj 1 mg per ml, 5 ml Inj 5 mg per ml, 3 ml Milrinone Inj 1 mg per ml, 10 ml Moclobemide Tab 150 mg Tab 300 mg Morphine Hydrochloride Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Morphine Sulphate Cap long-acting 10 mg Cap long-acting 30 mg Cap long-acting 60 mg Cap long-acting 100 mg Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Tab immediate release 10 mg Tab immediate release 20 mg Tab long-acting 10 mg Tab long-acting 30 mg Tab long-acting 60 mg 2,944,101 1,014,236 407,958 299,552 22,986 11,669 1,289,061 659,111 772,937 388,234 185,167 $529,938 $267,758 $293,730 $235,148 $23,768 $10,969 $340,312 $336,147 $139,129 $139,764 $133,320 $0.1800 $0.2640 $0.7200 $0.7850 $1.0340 $0.9400 $0.2640 $0.5100 $0.1800 $0.3600 $0.7200 C H C H C H C H C H C H C H C H C H C H C H 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 5,435,380 714,066 1,004,181 585,791 $219,046 $30,562 $48,251 $36,788 $0.0403 $0.0428 $0.0481 $0.0628 C H C H C H C H 1% 1% 1% 1% 1,491,347 356,795 $147,494 $93,159 $0.0989 $0.2611 C H C H 1% 1% H 1% H H 1% 1% 627,525 $140,409 $0.2238 C 1,304,831 $70,670 $0.0542 C 1,204 834 $7,291 $13,764 $6.0560 $16.5036 C H C H 1% 1% 26,618 17,765 $12,928 $147,911 $0.4857 $8.3260 C H C H 1% 1% Units Cost Unit Subsidy DV Limit Comments

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Morphine Sulphate Tab long-acting 100 mg Morphine Tartrate Inj 80 mg per ml, 1.5 ml Inj 80 mg per ml, 5 ml Mucilaginous Laxatives Dry Dry-original flavour, regular texture only Sugar Free Mupirocin Nasal oint 2% Mycophenolate Mofetil Cap 250 mg Inj 500 mg Powder for oral liq 1 g per 5 ml Tab 500 mg Naproxen Tab 250 mg Tab 500 mg Nevirapine Oral suspension 10 mg per ml Oral suspension 50 mg per 5 ml Tab 200 mg Nicotinic Acid Tab 25 mg Tab 50 mg Tab 100 mg Tab 500 mg Noradrenaline Acid Tartrate Inj 0.1 mg per ml, 100 ml bag Norethisterone Tab 350 mcg Oestrogens Conjugated, equine tab 300 mcg 1,203,803 $129,409 $0.1075 * C 9,474,169 $806,432 $0.0851 C H 1% 725,913 $127,761 $0.1760 1,158,927 $58,873 $0.0508 C C C C

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

253,839

$215,763

$0.8500

C H

23,383 1,793

$94,467 $24,159

$4.0400 $13.4740

C H C H

1% 1%

52,686,510 7,344,541 1,074,077

$927,283 $129,264 $18,904

$0.0176 $0.0176 $0.0176

C H C H C H

1% 1% 1%

255,891

$528,824

$2.0666

C H H

1% 1% 1% 1%

9,177 446,759

$15,851 $1,846,544

$1.7273 $4.1332

C H C H

1,138,443 2,585,347

$47,815 $185,628

$0.0420 $0.0718

C H C H

1% 1%

43,764

$24,534

$0.5606

C H C H

1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

123,184

$656,571

$5.3300

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Oral Feed 1.5 KCal per ml Liq 774,764,134 $4,338,679 $0.0056 * C H 1%

Sole supply could be awarded for a range of flavours from only one supplier. This line item describes oral feed listed under the "Adult Products Standard" therapeutic subgroup in the Pharmaceutical Schedule. Sole supply could be awarded for a range of flavours from only one supplier. This line item describes oral feed listed under the "Adult Products Standard" therapeutic subgroup in the Pharmaceutical Schedule.

Units

Cost

Unit Subsidy

DV Limit

Comments

Liq with fibre

73,903,400

$413,859

$0.0056

C H

Oxaliplatin Inj 50 mg Inj 100 mg Oxycodone Hydrochloride Cap 5 mg Cap 10 mg Cap 20 mg Tab controlled-release 5 mg Tab controlled-release 10 mg Tab controlled-release 20 mg Tab controlled-release 40 mg Tab controlled-release 80 mg Oxytocin Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Pancuronium bromide Inj 2 mg per ml, 2 ml Paracetamol Suppos 125 mg Suppos 250 mg Tab modified-release 665 mg 69,308 62,963 $22,560 $39,415 $0.3255 $0.6260 C H C H C 1% 1%

Not currently listed on the Pharmaceutical Schedule

H PCT 1% H PCT 1%

512,539 346,876 233,842 345,357 709,346 524,147 173,489 112,353

$72,524 $96,778 $114,232 $129,682 $395,106 $496,105 $288,772 $325,992

$0.1415 $0.2790 $0.4885 $0.3755 $0.5570 $0.9465 $1.6645 $2.9015

C H C H C H C H C H C H C H C H

1% 1% 1% 1% 1% 1% 1% 1%

965 4,462 2,783

$1,042 $6,068 $5,121

$1.0800 $1.3600 $1.8400

C H C H C H

1% 1% 1%

Paraffin White soft or yellow soft (pack size 30 g or less) Pethidine Hydrochloride Inj 50 mg per ml, 1 ml 33,594 $25,196 $0.7500 C H 1% H 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Pethidine Hydrochloride Inj 50 mg per ml, 1.5 ml Inj 50 mg per ml, 2 ml Phenindione Tab 10 mg Tab 25 mg Tab 50 mg Phenoxybenzamine Inj 100 mg per 2 ml Pindolol Tab 5 mg Tab 10 mg Tab 15 mg Potassium Chloride Tab long-acting 600 mg Pregnancy Tests - HCG Urine Urine diagnostic test Propranolol Cap long-acting 160 mg Tab 10 mg Tab 40 mg Pyrantel Embonate Oral suspension Tab $0.2950 * C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule A variety of oral solid dose forms would be considered. Note this product has been discontinued.

Units

Cost

Unit Subsidy

DV Limit

Comments

201 71,687

$175 $59,930

$0.8700 $0.8360

C H C H

1% 1%

H H H

1% 1% 1%

311,631 318,076 155,255

$14,023 $26,559 $18,631

$0.0450 $0.0835 $0.1200

C H C H C H

1% 1% 1%

11,543,083

$300,120

$0.0260

C H

361,483

$274,727

$0.7600

C H

657,431 1,986,827 2,286,674

$111,106 $70,532 $106,330

$0.1690 $0.0355 $0.0465

C H C H C H

1% 1% 1%

Pyridoxine Hydrochloride Tab 50 mg Quinine Sulphate Tab 200 mg Tab 300 mg Raloxifene Tab 60 mg C H 1%

Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to an endorsement or Special Authority restriction

1,329,155

$46,866

$0.0353

1,894,387 3,544,411

$120,862 $246,337

$0.0638 $0.0695

C H C H

1% 1%

Rasburicase Inj 1.5 mg H 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Rocuronium Inj 10 mg per ml, 5 ml Inj 10 mg per ml, 10 ml Roxithromycin Tab 150 mg Tab 300 mg Salbutamol Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Salbutamol with Ipratropium Bromide Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml Selegiline Hydrochloride Tab 5 mg Sodium Bicarbonate Inj 8.4%, 50 ml Inj 8.4% 100 ml Inf 5%, 500 ml Powder BP Sodium Cromoglycate Eye drops 2% Nasal spray, 4% Sodium Hyaluronate Inj 3% with 4% chondroitin sulphate, 0.35 ml Inj 3% with 4% chondroitin sulphate, 0.5 ml Ophthalmic inj 14 mg per ml Ophthalmic soln 10 mg per ml Sodium Hyaluronidate Inj 14 mg per ml Streptomycin Inj 1 g Testosterone Transdermal patch 2.5 mg per day Tetrabenazine Tab 25 mg 111,640 $242,219 $2.1696 C 104,975 $139,963 $1.3333 C H 1% H 1% H 1% H H H H 1% 1% 1% 1% 442,865 49,813 $174,932 $30,567 $0.3950 $0.6136 C C 168,898 $3,310 $0.0196 1,927 2,203 $38,444 $45,162 $19.9500 $20.5000 C H C H H C H 1% 1% 1% 1% 179,760 $28,869 $0.1606 C 1,256,489 $332,970 $0.2650 C H 1% 441,581 1,052,618 $81,692 $202,629 $0.1850 $0.1925 C H C H 1% 1% 1,711,147 700,273 $325,118 $252,098 $0.1900 $0.3600 C H C H 1% 1% H H 1% 1% Units Cost Unit Subsidy DV Limit Comments

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Tetracycline Hydrochloride Cap 250 mg C H 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

Thiamine Hydrochloride Inj 100 mg per ml, 2 ml C H 1%

Not currently listed on the Pharmaceutical Schedule

Ticarcillin Inj 1 g Inj 3 g H H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Timolol maleate Tab 10 mg Tranexamic Acid Inj 100 mg per ml, 5 ml Travoprost Eye drops 0.004% 94,418 $736,460 $7.8000 C H 1% 193,209 $20,384 $0.1055 C

Triamcinolone acetonide with gramicidin, neomycin and nystatin Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Tropisetron Cap 5 mg Inj 1 mg per ml, 2 ml 8,623 $133,501 $15.4820 C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule

176,287

$78,742

$0.4467

C H

Urokinase Inj 10,000 iu Inj 500,000 iu Vecuronium Inj 4 mg Inj 10 mg Vincristine Sulphate Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Vinorelbine Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 5 ml Vitamin B Complex Tab, strong, BPC 2,181,455 $52,791 $0.0242 C H PCT 1% H PCT 1% H PCT 1% H PCT 1% H H 1% 1% H H 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Vitamins Tab (BPC cap strength) Zidovudine (AZT) with Lamivudine Tab 300 mg with lamivudine 150 mg Zuclopenthixol Hydrochloride Tab 2 mg Tab 10 mg Tab 25 mg Tab 40 mg C H C H C H C H 1% 1% 1% 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

26,540,856

$392,805

$0.0148

363,685

$4,044,177

$11.1200

Metadata

Title

Tender 2008 - letter to pharmaceutical suppliers and interested parties - ACPs close 15 October, other responses close 5 November 2008

Abstract

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.